Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.

Inclusion Criteria:Histologically confirmed, documented diagnosis of Stage IV metastatic, NSCLCEastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1At least one measurable target lesion per RECIST v1.1.Adequate organ and marrow functionParticipants must be willing to provide adequate tumor tissueExclusion Criteria:Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardousUse of any live vaccines against infectious diseases within 28 days of first dose of IP(s).Concurrent chronic medical condition requiring the use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications (absorbable topical corticosteroids are not excluded).Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopyNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.